FDA Imposes Boxed Warning and Restricts Use of Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy on November 17, 2025 Black Box Warning Elevidys gene therapy Indication restriction Liver Failure, Acute Muscular Dystrophy, Duchenne Post-marketing study Safety labeling United States Food and Drug Administration +